{
  "index": 130,
  "timestamp": "2024-11-11 22:53:25",
  "original_text": "For Immediate Release: December 20, 2021 Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents ...",
  "qa_pairs": [
    {
      "text_input": "What is the name of the new HIV PrEP medication approved by the FDA?",
      "output": "Apretude (cabotegravir extended-release injectable suspension)",
      "index": 130,
      "timestamp": "2024-11-11 22:53:25"
    },
    {
      "text_input": "How often is Apretude administered?",
      "output": "Every two months after two initiation injections one month apart",
      "index": 130,
      "timestamp": "2024-11-11 22:53:25"
    },
    {
      "text_input": "What percentage of individuals at risk for HIV in the US were prescribed PrEP in 2020?",
      "output": "About 25%",
      "index": 130,
      "timestamp": "2024-11-11 22:53:25"
    }
  ]
}